Where would you like to sign in?

CancerVax Corporation to Host Conference Call and Live Webcast to Discuss First Quarter 2005 Financial Results

CARLSBAD, CA -- (MARKET WIRE) -- May 2, 2005 -- CancerVax Corporation (NASDAQ: CNVX), a
biotechnology company focused on the research, development and
commercialization of novel biological products for the treatment and
control of cancer, will host a conference call and live webcast on
Thursday, May 5, 2005 at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss financial
results for the first quarter ended March 30, 2005.

President and CEO David F. Hale will provide an update of the Company's
pipeline of biological products for the treatment and control of cancer. In
particular, he will discuss the ongoing development and commercialization
of Canvaxin™, an investigational specific active immunotherapy product
in a Phase 3 clinical trial for patients with Stage III melanoma.

The conference call will be webcast simultaneously over the Internet. To
listen, please visit the Investor Relations section of CancerVax's
corporate web site at http://ir.cancervax.com. The webcast will be
archived on this site for one year. Alternatively, callers may participate
in the conference call by dialing (800) 706-7748 (domestic) or
(617) 614-3473 (international). The passcode is 36028320. A replay of the
conference call can be accessed by dialing (888) 286-8010 (domestic) or
(617) 801-6888 (international) and the passcode is 64695774.

CancerVax Corporation is a biotechnology company focused on the research,
development and commercialization of novel biological products for the
treatment and control of cancer. The Company's lead product candidate,
Canvaxin™, is one of a new class of products being developed in the area
of specific active immunotherapy, also known as therapeutic cancer
vaccines. Canvaxin is being evaluated in a Phase 3 clinical trial for the
treatment of patients with Stage III melanoma. In December 2004, CancerVax
announced an exclusive worldwide collaboration with Serono Technologies,
S.A., a Swiss corporation, for the development and commercialization of
Canvaxin. CancerVax also has a pipeline of product candidates and
technologies that are being developed for the potential treatment of
cancer. These include: SAI-EGF, a product candidate that targets the
epidermal growth factor (EGF) receptor signaling pathway, which is
currently being evaluated in Phase 2 clinical trials for the treatment of
non-small-cell lung cancer; D93, CancerVax's lead anti-angiogenic humanized
monoclonal antibody; and certain telomere signaling T-oligionucleotide
technology in preclinical research and development.

Forward-Looking Statements

CancerVax cautions you that statements included in this press release that
are not a description of historical facts are forward-looking statements.
For example, statements about the timing and outcomes of its clinical
trials, and plans and objectives of management, are all forward-looking
statements. The inclusion of forward-looking statements should not be
regarded as a representation by CancerVax that any of its plans will be
achieved. Actual results may differ materially from those set forth in this
release due to the risks and uncertainties inherent in CancerVax's business
including, without limitation, statements about: the progress and timing of
its clinical trials, including the planned continuation and eventual
outcome of the trials, the potential for the trials to serve as pivotal
trials for regulatory purposes, and the anticipated filing of regulatory
approvals; difficulties or delays in developing, testing, obtaining
regulatory approval, producing and marketing its product candidates; the
risk that the collaboration agreement for Canvaxin may be terminated by
Serono; and other risks detailed in CancerVax's Securities and Exchange
Commission filings, including CancerVax's Annual Report on Form 10-K for
the fiscal year ended December 31, 2004. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
the date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement and CancerVax undertakes no
obligation to revise or update this news release to reflect events or
circumstances after the date hereof. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.